Costs for primary life-saving procedures in case of acute clinical syndromes as myocardial infarction (MI) and chronic heart failures (CHFs) are gradually increasing while the medical management of the chronic sequalae of the acute syndromes remains mainly based on standard classic approaches such as β-adrenergic receptor blocking agents, angiotensin-converting enzyme (ACE) inhibitors and mineralocorticoid-receptor antagonists [2,3]. This evidence concerns the gene ACE and congestive heart failure.